Home > Insider Trading > Filing (0001209191-20-043880)

Filing Details

Accession Number:: 0001209191-20-043880
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-28 18:26:04
Reporting Period:: 2020-07-28

Accepted Time:: 2020-07-28 18:26:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693011	Inozyme Pharma Inc.	INZY	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1629794	New Enterprise Associates 15, L.p.	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1640031	Nea Partners 15, L.p.	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1640033	Nea 15 Gp, Llc	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-07-28	2,000,533	$0.00	2,000,533	No	4	C	Direct
Common Stock	Acquisiton	2020-07-28	187,156	$0.00	2,187,689	No	4	C	Direct
Common Stock	Acquisiton	2020-07-28	250,000	$16.00	2,437,689	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-07-28	2,000,533	$0.00	2,000,533	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2020-07-28	187,156	$0.00	187,156	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

On July 28, 2020, the Series A Preferred Stock converted into Common Stock on a 7.473-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The shares are directly held by New Enterprise Associates 15, L.P. ("NEA 15"), and indirectly held by NEA Partners 15, L.P. ("NEA Partners 15"), the sole general partner of NEA 15, NEA 15 GP, LLC ("NEA 15 GP"), the sole general partner of NEA Partners 15, and the individual managers of NEA 15 GP (NEA Partners 15, NEA 15 GP and the individual managers of NEA 15 GP, together, the "Indirect Reporting Persons"). The individual managers of NEA 15 GP are Forest Baskett, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, Scott D. Sandell and Peter W. Sonsini. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 15 shares in which the Indirect Reporting Persons have no pecuniary interest.
On July 28, 2020, the Series A-2 Preferred Stock converted into Common Stock on a 7.473-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.